- Home
- KALA vs AIXI Comparison
KALA vs AIXI Comparison
Compare KALA & AIXI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KALA
- AIXI
- Stock Information
- Founded
- KALA 2009
- AIXI 2001
- Country
- KALA United States
- AIXI China
- Employees
- KALA N/A
- AIXI N/A
- Industry
- KALA Biotechnology: Pharmaceutical Preparations
- AIXI Computer Software: Prepackaged Software
- Sector
- KALA Health Care
- AIXI Technology
- Exchange
- KALA Nasdaq
- AIXI Nasdaq
- Market Cap
- KALA 26.2M
- AIXI 31.2M
- IPO Year
- KALA 2017
- AIXI 2023
- Fundamental
- Price
- KALA $6.62
- AIXI $2.39
- Analyst Decision
- KALA Strong Buy
- AIXI
- Analyst Count
- KALA 3
- AIXI 0
- Target Price
- KALA $14.00
- AIXI N/A
- AVG Volume (30 Days)
- KALA 117.3K
- AIXI 133.8K
- Earning Date
- KALA 08-05-2025
- AIXI 05-15-2025
- Dividend Yield
- KALA N/A
- AIXI N/A
- EPS Growth
- KALA N/A
- AIXI N/A
- EPS
- KALA N/A
- AIXI N/A
- Revenue
- KALA N/A
- AIXI $70,314,315.00
- Revenue This Year
- KALA N/A
- AIXI $26.84
- Revenue Next Year
- KALA N/A
- AIXI N/A
- P/E Ratio
- KALA N/A
- AIXI N/A
- Revenue Growth
- KALA N/A
- AIXI 18.84
- 52 Week Low
- KALA $2.92
- AIXI $2.06
- 52 Week High
- KALA $11.20
- AIXI $8.31
- Technical
- Relative Strength Index (RSI)
- KALA 77.24
- AIXI 41.81
- Support Level
- KALA $4.36
- AIXI $2.20
- Resistance Level
- KALA $5.75
- AIXI $2.60
- Average True Range (ATR)
- KALA 0.66
- AIXI 0.31
- MACD
- KALA 0.20
- AIXI -0.01
- Stochastic Oscillator
- KALA 96.85
- AIXI 23.33
About KALA KALA BIO Inc.
Kala Bio Inc is a biopharmaceutical company. The company is a clinical-stage biopharmaceutical company dedicated to researching, developing, and commercializing therapies for rare and severe eye diseases. KALA'smain product candidate, KPI-012, is a human MSC-S, which contains numerous human-derived biofactors, such as growth factors, protease inhibitors, matrix proteins, and neurotrophic factors that can potentially correct the impaired corneal healing that is an underlying etiology of multiple severe ocular diseases. Its MSC-S platform is for retinal degenerative diseases, such as Retinitis Pigmentosa and Stargardt Disease.
About AIXI XIAO-I Corporation
XIAO-I Corp is an AI industrialization company focusing on the AI Cognitive Intelligence platform. The platform combines six core technologies including Natural Language Processing, Speech Processing, Computer Vision, Machine Learning, Affective Computing, Data Intelligence, and Hyper- automation. Based on the platform, The company developed products and solutions in the fields of Al+ Contact Center, Al+ Finance, Al+ City Public Service, Al+ Architecture, Al+ Metaverse, Al+ Manufacturing, and Al+ Healthcare. It generates revenue from the sale of software products and services, M&S services, and the sale of cloud platform products.